Qomatropin 100 iu 10 vials

Human Growth Hormone also known as Somatropin, is a polypeptide hormone produced by anterior pituitary gland in brain. It has 191 amino acids. It is mainly indicated for children who have growth failure due to lack of endogeneous growth. Growth Hormone has significant effects on skeletal growth, carbohydrate metabolism, lipid metabolism, mineral metabolism and connective tissue metabolism. Main functions of growth hormone are that it promotes tissue repair, cell regeneration in bones, and supports immune system in combating infection and disease.Qomatropin is indicated: growth failure; Turner Syndrome; Somatropin Deficiency Syndrome; Small for Gestational Age (SGA); Idiopathic Short Stature; Prader-Will Syndrome; Adult with AIDS wasting.Before injection, slowly dissolve the lyophilized Somatropin powder with 1ml sterile water for injection or bacteriostatic water for injection.The recommended dosage of Qomatropin is 0.1 IU/kg body weight once daily. It is usually given in the evening before sleep, preferably in the abdominal area. The injection site should change regularly to prevent lipoatrophy.Contraindications: Patients with closed epiphysis. Evidence of tumor activity or active neoplasia (intracranial lesions must be inactive and antitumor therapy completed prior to instituting therapy). Qomatropin must be discontinued if there is evidence of tumor activity. Patients allergic to any component of the product.There is no clinical experience on the use of Qomatropin in patients aged more than 60 years.Leukemia has occurred in a small number of children receiving Qomatropin, although the relationship is uncertain.Approximately 2% of patients develop antibodies. Of the 232 patients receiving Qomatropin for 6 months, 4.7% had serum binding of radiolabeled growth hormone in excess of twice the binding observed in control sera.Qomatropin may cause headaches, localized muscle pain, arthralgia, carpal tunnel syndrome, weakness, mild hyperglycemia, and glucosuria. Mild transient edema occurs in 2.5% of patients early during treatment. Local urticarial reactions have rarely been reported at the injection site.